Curanex 10-Q: $9.26M Nine-Month Loss, $1.58M Cash, Going-Concern Doubt
CURX sits 30% above its 52-week low of $3.576 on light trading volume (0.3× avg).
Summary
Curanex ended Q3 2026 with $1.58M of cash against a $9.26M nine-month loss and disclosed substantial doubt about its ability to continue as a going concern, with prepaid R&D buffers nearly used up and two IPO class actions pending.
Key Events · Earnings and Guidance · CURX
-
Going-Concern Warning on Thin Cash
Cash and cash equivalents were $1,579,689 at September 30, 2026, down from $4,973,134 at December 31, 2025. Management says existing cash will not fund operations for at least twelve months, and because the capital-raising plans are not considered probable, substantial doubt remains.
-
Nine-Month Loss Widens to $9.26M
Net loss was $9,256,795 for the nine months ended September 30, 2026 versus $1,151,988 a year earlier, driven by R&D of $6,802,466 (up from $679,574) and G&A of $2,536,161 (up from $466,863).
-
Prepaid R&D Buffer Nearly Exhausted
Prepaid R&D fell to $314,783 from $6,166,294 at December 31, 2025, so the $3,393,445 of operating cash used in the period understates future burn; cash use is expected to rise toward the expense run rate.
-
Disclosure Controls Deemed Ineffective
Management concluded disclosure controls and procedures were not effective as of September 30, 2026, a first-time adverse conclusion in this filing.
Analysis · CURX · Life Sciences
Most of the IPO cash is gone: cash fell to $1,579,689 from $4,973,134 at year-end 2025, while the nine-month net loss widened to $9,256,795 from $1,151,988 a year earlier. Management states plainly that existing cash will not fund operations for at least twelve months and that the capital-raising plans are not considered probable, so the substantial-doubt language stands. The burn understates the real run rate because $5.85M of R&D was paid from prepaid balances that are now nearly exhausted ($314,783 left versus $6,166,294), meaning cash use should jump toward the expense line. Layered on top are two IPO-related securities class actions and a first-time conclusion that disclosure controls were not effective. A financing is needed, and any equity raise at a $7.3M market cap would be heavily dilutive to the 1,568,216 shares outstanding.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CURX was trading at $4.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.3M. The 52-week trading range was $3.58 to $13.33. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.